EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Treatment of acute kidney injury with continuous renal replacement therapy and cytokine adsorber ( CytoSorb ®) in critically ill patients with COVID ‐19

Eva Jakopin iD, Maša Knehtl iD, Nina Vodošek Hojs, Sebastjan Bevc iD, Nejc Piko iD, Radovan Hojs, Robert Ekart

Therapeutic Apheresis and Dialysis · 2024

DOI: 10.1111/1744-9987.14182 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Apheresis and Dialysis, 2024. Verfasst von Eva Jakopin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Clinic for Internal Medicine, University Medical Centre Maribor, Maribor, Slovenia. Hauptthemen laut MEDLINE: Acute Kidney Injury, COVID-19, Continuous Renal Replacement Therapy, Critical Illness. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

This retrospective study aimed to evaluate the 30 and 60‐day survival of critically ill patients with COVID‐19 and AKI.

Methods

Inflammatory and biochemical biomarkers, length of intensive care unit (ICU) stay and mortality at Day 30 and Day 60 after ICU admission were analyzed. A total of 44 patients treated with continuous renal replacement therapy (CRRT) with cytokine adsorber (CA group) were compared to 58 patients treated with CRRT alone (non‐CA group).

Results

Patients in CA group were younger, had better preserved kidney function prior to the beginning of CRRT and had higher levels of interleukin‐6. There were no statistically significant differences in their comorbidities and in other measured biomarkers between the two groups. The number of patients who died 60 days after ICU admission was statistically significantly higher in non‐CA group ( p = 0.029).

Conclusion

Treatment with CRRT and cytokine adsorber may have positively influenced 60‐day survival in our COVID‐19 ICU patients with AKI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Kidney InjuryCOVID-19Continuous Renal Replacement TherapyCritical IllnessCytokinesIntensive Care UnitsHumansMaleFemaleRetrospective StudiesMiddle AgedAgedSARS-CoV-2Length of StayBiomarkers

Stichwörter der Autor:innen

COVID‐19acute kidney injurycontinuous renal replacement therapycytokine adsorption

Substanzen

CytokinesBiomarkers

Autor:innen und Institutionen

  • Department of Nephrology, Clinic for Internal Medicine, University Medical Centre Maribor, Maribor, Slovenia.
  • Medical Faculty, University of Maribor, Maribor, Slovenia.
  • Department of Dialysis, Clinic for Internal Medicine, University Medical Centre Maribor, Maribor, Slovenia.

ORCID-Profile: Eva Jakopin, Maša Knehtl, Sebastjan Bevc, Nejc Piko

Zitieren

APA

Jakopin, E., Knehtl, M., Hojs, N. V., Bevc, S., Piko, N., Hojs, R., & Ekart, R. (2024). Treatment of acute kidney injury with continuous renal replacement therapy and cytokine adsorber ( CytoSorb ®) in critically ill patients with COVID ‐19. Therapeutic Apheresis and Dialysis. https://doi.org/10.1111/1744-9987.14182

Vancouver

Jakopin E, Knehtl M, Hojs NV, Bevc S, Piko N, Hojs R, et al. Treatment of acute kidney injury with continuous renal replacement therapy and cytokine adsorber ( CytoSorb ®) in critically ill patients with COVID ‐19. Therapeutic Apheresis and Dialysis. 2024. doi:10.1111/1744-9987.14182

BibTeX
@article{Jakopin2024,
  author = {Jakopin, Eva and Knehtl, Maša and Hojs, Nina Vodošek and Bevc, Sebastjan and Piko, Nejc and Hojs, Radovan and Ekart, Robert},
  title = {Treatment of acute kidney injury with continuous renal replacement therapy and cytokine adsorber ( CytoSorb ®) in critically ill patients with COVID ‐19},
  journal = {Therapeutic Apheresis and Dialysis},
  year = {2024},
  doi = {10.1111/1744-9987.14182}
}
Kostenlos starten →